NIH SBIR Phase I budgets in 2026 must be calculated against a 15% F&A (indirect cost) cap, down from the roughly 40% rate that most small-business applicants applied (academic spinouts often inherited higher institutional rates). On a standard $250K direct-cost modular budget, that drops allowable indirect recovery from $100,000 at 40% to $37,500 at 15% -- a $62,500 reduction per year that founders have to absorb through budget restructuring, not appeal. If your prior rate was 35% you lose about $50,000; at 50% you lose $87,500. The exact gap scales linearly with whatever rate you used to apply.
This guide walks through the exact math, three rebudgeting strategies founders are actually using, and the line items where the cut bites hardest. If you have a 12-month Phase I going in this cycle, the reading order is: math first, strategies second, narrative third.
What changed: from a negotiated F&A rate to a 15% cap
F&A stands for "facilities and administrative" costs. In plain English: the share of overhead (rent, utilities, accounting, IT, shared lab fees, administrative staff time) that the federal government will reimburse on top of your direct project costs.
Before 2026, NIH SBIR applicants typically applied either their company's negotiated indirect cost rate or, more often for small businesses without a federally negotiated rate, a default rate around 40%. Many academic spinouts inherited their parent institution's higher rate.
In 2026, NIH applied a 15% cap on the F&A rate for SBIR awards. The cap is not negotiable at the application level. Whatever your company's actual overhead is, the federal portion is capped at 15% of allowable direct costs.
What is the new NIH SBIR indirect cost rate? The NIH SBIR indirect cost (F&A) rate is capped at 15% of modified total direct costs for Phase I and Phase II SBIR/STTR awards in FY2026. This applies regardless of the applicant's negotiated rate. The rate replaces the prior practice of applying negotiated rates (often 30-50%) or the small-business default rate of approximately 40%.
Implementation specifics may vary by IC (Institute or Center) business office, and subcontractor treatment in particular is still being interpreted as of mid-2026. Confirm with your grants management specialist before submission.
How the 15% F&A cap actually affects your Phase I budget
Most Phase I applications use the modular budget format: direct costs requested in $25K increments, up to $250K per year. F&A is then layered on top of direct costs.
The math under the old assumption looked like this:
- $250,000 direct costs + 40% F&A = $350,000 total per year
Under the 2026 rule, it looks like this:
- $250,000 direct costs + 15% F&A = $287,500 total per year
That is a $62,500 reduction per year on a maxed-out modular budget. On a 12-month Phase I, that is the loss. On the rare 24-month Phase I, double it.
How much does the 15% F&A cap reduce my SBIR budget? On a standard $250K direct-cost modular Phase I budget, the 15% F&A cap reduces the total request by approximately $62,500 per year compared to a 40% negotiated rate, and approximately $50,000 per year compared to a 35% rate. The reduction is not paid -- it must be absorbed by the company or removed from scope.
There is a related ceiling effect. The SBA cap on a Phase I award is $314,363 total. If you request $300K in direct costs, the 15% F&A pushes you against the SBA cap regardless of any negotiated rate. The cap binds.
Worked budget example: a Phase I before and after the 15% cap
To make the math concrete, consider an illustrative scenario. A fictional synthetic-biology startup ("SynthCo" -- not a real company, used here for illustration only) is applying for an NIH SBIR Phase I to develop a new enzyme assay. The team is one PI, one senior scientist, one research associate. No subcontracts. Standard 12-month modular Phase I.
| Line item | Amount | F&A eligible? |
|---|---|---|
| PI salary (20% effort) | $50,000 | Yes |
| Senior scientist (75% effort) | $90,000 | Yes |
| Research associate (50% effort) | $35,000 | Yes |
| Fringe benefits at 28% | $49,000 | Yes |
| Lab supplies and consumables | $18,000 | Yes |
| Travel (one meeting + visits) | $4,000 | Yes |
| Other (publication, software) | $4,000 | Yes |
| Total direct costs | $250,000 | -- |
Under the old 40% F&A:
- Direct costs: $250,000
- F&A: $100,000
- Total request: $350,000
Under the 15% cap:
- Direct costs: $250,000
- F&A: $37,500
- Total request: $287,500
The "missing" $62,500 does not reappear elsewhere in the budget. It is not an accounting trick. It is real overhead -- rent, shared lab fees, accounting -- that the company now pays out of its own resources rather than being reimbursed.
For a fictional second scenario, imagine the same startup adds an $80,000 subcontract to a university lab for a specialized assay. The subcontract is 32% of direct costs (under the 33% SBIR cap). On the prime side, only the first $25,000 of the subcontract counts toward the F&A base under modified total direct cost (MTDC) rules. So the F&A base is roughly $195,000, and the prime's F&A at 15% is $29,250. The subcontractor's own F&A is calculated separately on the subcontract amount per their negotiated rate and is included within the $80,000.
If you calculate F&A on the full $250,000 without removing the post-$25K subcontract amount from the base, you over-request F&A by several thousand dollars. This is one of the easiest mistakes to make and the easiest for a grants management specialist to catch and reject.
Three rebudgeting strategies founders are actually using
How do I rebudget my NIH SBIR Phase I for the 15% F&A cap? There are three real options: reduce subcontractor scope to bring more F&A-eligible work in-house, shift project-specific costs (cloud computing, dedicated software, project-tied IT) from indirect to direct categories with explicit justification, or cut scope to match the smaller total budget. Most successful rebudgets combine two of these, not all three.
None of these are loopholes. They are scope decisions.
Strategy 1: Reduce subcontractor scope
If your subcontract was convenience-driven rather than capability-driven, bringing work in-house reduces the subcontract line and increases F&A-eligible direct costs in your own personnel and supplies categories. The 33% SBIR subcontracting cap is a maximum, not a target.
This works only if:
- The small business has the capability or can hire it
- The scientific approach does not depend on the subcontractor's specific expertise
- The reduced subcontract scope still makes scientific sense
It does not work if the subcontractor is providing specialized animal models, clinical site access, or core facility services that the small business genuinely cannot replicate.
Strategy 2: Shift indirect-eligible costs into direct cost categories
Some costs that were previously absorbed in indirect can be moved into direct cost categories with explicit justification. For example: project-specific cloud computing, dedicated lab space allocations measurable to this project, project-specific software licenses, and IT support that can be tied to this work specifically.
This requires care. The cost must be:
- Specifically and exclusively for this project (not general overhead)
- Allowable under cost principles (2 CFR 200)
- Documented in the budget justification narrative
The thing to avoid is "rebadging" general overhead as direct. A reviewer who sees "office rent" or "general administrative time" in the direct cost column will flag it. Grants management specialists kick budgets back for this regularly.
Strategy 3: Adjust effort and milestones
Sometimes the rebudget cannot recover the F&A loss, and direct cost reduction is required. This usually means re-scoping milestones to match a smaller budget: a 9-month aim instead of 12, one fewer scientist, a tighter set of experiments per aim.
The constraints:
- Aims must remain achievable in the proposed timeline
- PI must remain primarily employed (at least 51%) by the small business during the award
- The scientific story must hold together at the reduced scope -- a thin Phase I is worse than no Phase I
If you find yourself rebudgeting by cutting the science to fit the F&A cap, that is a signal the original budget was too tight to begin with.
What absorbs the cut: line items where the 15% cap actually bites
The F&A cap does not eliminate overhead. It shifts who pays for it.
For founders in incubators or shared lab space, the math gets worse. Shared facilities allocate overhead per square foot or per FTE, and that overhead does not go away just because the federal portion is capped.
For founders working from home or running a cloud-only computational shop, the math gets less bad. There is less overhead to absorb in the first place.
Common pain points where the cut shows up most:
- Rent and utilities allocated to the project
- Shared lab fees in incubator settings
- Accounting, legal, and IT support
- Administrative staff time (grants administration, HR, compliance)
If your company's overhead is genuinely above 15% of direct costs (which it almost certainly is), the difference comes out of the company's own funding -- equity dilution, cash on hand, founder runway.
Subcontractor F&A: the easy mistake to avoid
Does the 15% F&A cap apply to my subcontractor's indirect costs? No. The 15% cap applies only to the prime applicant's F&A on its own direct costs. The subcontractor charges F&A at its own negotiated rate (often higher, e.g., 60% for a university) on the subcontract amount, and that subcontractor F&A is included within the subcontract line item rather than added on top. Under MTDC rules, only the first $25,000 of each subcontract counts toward the prime's F&A base.
Two things are easy to confuse:
- The 15% cap on the prime applicant's F&A. This is what NIH reimburses the small business for its own indirect costs.
- The subcontractor's own F&A rate. This is calculated on the subcontract amount per the subcontractor's negotiated rate (or de minimis rate) and is included as part of the subcontract line item.
A common error: applicants assume the 15% cap applies to the subcontractor too. It does not. The subcontractor's rate is what their institution has negotiated. If a university subcontractor's negotiated rate is 60%, that is what they will charge against the subcontract amount, and the prime will pass that through.
The other related error: forgetting MTDC. Under modified total direct cost rules, only the first $25,000 of each subcontract counts toward the prime's F&A base. If you have an $80,000 subcontract, $55,000 of that is excluded from the prime's F&A base.
Subcontract F&A treatment under the new cap is still being interpreted by IC business offices, and the specific MTDC application to SBIR has historically been inconsistent across ICs. Confirm with your grants management specialist before submission.
Three things to fix in your budget justification narrative
Don't just scale numbers and call it done. The justification needs to reflect the new constraint.
-
State the F&A rate explicitly. "Indirect costs requested at the 15% cap applicable to NIH SBIR awards in FY2026" is a one-sentence fix that prevents reviewer confusion.
-
Don't appeal in the justification. The cap is set at the policy level, not the application level. Asking for a higher rate in the budget justification narrative is a reviewer flag and a waste of space.
-
Avoid F&A-eligible expenses showing up as direct costs without solid justification. If you're using Strategy 2 (shifting costs to direct), every shifted cost needs an explicit, project-specific justification. "General lab supplies" is not enough; "consumables for the assay development described in Aim 2 (specific list, estimated quantity, and unit cost)" is.
Frequently asked questions
When does the 15% F&A cap take effect?
For NIH SBIR Phase I and Phase II awards in FY2026 onward. Applications submitted under the FY2026 omnibus parent FOA must use the 15% rate. Confirm the specific FOA language in the funding opportunity announcement.
Does the 15% cap apply to STTR awards too?
Yes, the 15% cap applies to STTR awards under the same NIH policy. STTR's separate cost-sharing rule (small business at least 40%, research institution at least 30% of work) is unchanged.
Can I appeal or negotiate a higher rate?
No. The cap is set at the policy level. There is no application-level negotiation path.
How does this affect Phase II budgets?
The same 15% cap applies. Phase II awards are larger (well above $1M total under current SBA caps -- check the current SBA cap for the specific year), so the absolute dollar reduction is bigger. The math is the same: 15% of allowable direct costs, capped.
Does this change the $314,363 SBA award cap?
No. The SBA cap on Phase I total awards remains $314,363. What changed is how much of that ceiling can be indirect costs. With the 15% cap and the SBA ceiling combined, requesting more than $250K in direct costs starts pushing you against the SBA ceiling.
A straight offer for NIH SBIR applicants navigating the 2026 indirect cost rate
If you're not sure whether your rebudgeted Phase I still tells a coherent story under the new NIH SBIR indirect cost rate, that's worth a second pair of eyes before submission. Cada does a free 15-minute budget review for NIH SBIR applicants -- straight feedback on whether the budget math, scope, and narrative still line up. No pitch, no obligation. We do this because we'd rather you submit a competitive application than a compliant-but-thin one.
The harder question is not "does my budget comply with 15% F&A?" It is "does the science I can afford under 15% F&A still win in study section?" That's a separate problem, and it's the one we spend most of our time on.